- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01789736
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
February 17, 2014 updated by: Aerie Pharmaceuticals
A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost.
The hypothesis is that there is no difference between each treatment arm.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
234
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Artesia, California, United States, 90701
- Kenneth Sall, M.D.
-
Inglewood, California, United States, 90301
- United Medical Research Institute
-
Newport Beach, California, United States, 92657
- Aesthetic Eye Care Institute
-
Petaluma, California, United States, 94954
- Bacharach practice
-
Poway, California, United States, 92064
- Centre For Health Care
-
-
Georgia
-
Morrow, Georgia, United States, 30260
- Clayton Eye Center
-
Roswell, Georgia, United States, 30076
- Coastal Research Associates, LLC
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66204
- Bradley Kwapiszeski, MD
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Taustine Eye Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21209
- Alan L Robin, M.D.
-
Havre de Grace, Maryland, United States, 21078
- Seidenberg Protzko Eye Associates
-
-
Michigan
-
St Joseph, Michigan, United States, 49085
- Great Lakes Eye Care
-
-
New York
-
Bronx, New York, United States, 10467
- Jeffrey Schultz, M.D.
-
Lynbrook, New York, United States, 11563
- Ophthalmic Consultants of Long Island
-
Rochester, New York, United States, 14618
- Rochester Ophthalmological Group
-
-
North Carolina
-
Belmont, North Carolina, United States, 28012
- Charlotte Eye Ear Nose & Throat Associates, P.A.
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- The Eye Institute
-
-
Texas
-
Austin, Texas, United States, 78731
- Texan Eye
-
San Antonio, Texas, United States, 78731
- Medical Center Ophth. Associates
-
-
Utah
-
Salt Lake City, Utah, United States, 84117
- Stacy R. Smith, M.D.
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Virginia Eye Consultants
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Subject inclusion criteria
- 18 years of age or greater.
- Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Unmedicated (post-washout) IOP ≥ 22 mm Hg at 2 qualification visits (08:00 hr), 2-7 days apart. At second qualification visit, IOP >21 mmHg at 10:00 and 16:00 hrs.
- Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- Able and willing to give signed informed consent and follow study instructions.
Subject exclusion criteria
Excluded from the study will be individuals with the following characteristics:
Ophthalmic (in either eye):
- Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
- Intraocular pressure > 35 mm Hg, or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.
- Known hypersensitivity to any component of the formulation (benzalkonium chloride, zinc, etc.), travoprost, or to topical anesthetics.
- Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).
- Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).
- Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.
- Evidence of ocular infection, inflammation, clinically significant blepharitis, conjunctivitis, or a history of herpes simplex keratitis at screening.
- Ocular medication of any kind within 30 days of screening, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after screening) or c) lubricating drops for dry eye (which may be used throughout the study).
- Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (e.g., cup-disc ratio > 0.8).
- Central corneal thickness greater than 600 µm.
Any abnormality preventing reliable applanation tonometry of either eye.
Systemic:
- Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.
- Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- Participation in any investigational study within 30 days prior to screening.
- Changes of systemic medication within 30 days prior to screening, or anticipated during the study, that could have a substantial effect on IOP.
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PG286
PG286 Ophthalmic Solution q.d.
O.U.
|
PG286 Ophthalmic Solution
|
Experimental: AR-12286 Ophthalmic Solution 0.5%
AR-12286 Ophthalmic Solution 0.5% q.d.
O.U.
|
AR-12286 Ophthalmic Solution 0.5%
|
Active Comparator: Travoprost 0.004%
Travoprost 0.004% q.d. O.U.
|
Travoprost Ophthalmic Solution 0.004%
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean diurnal IOP
Time Frame: 28 Days
|
The primary efficacy endpoint will be the mean diurnal IOP across subjects within treatment group and time point at Day 28.
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IOP
Time Frame: 7-28 days
|
Secondary efficacy endpoints will include: mean IOP across subjects within treatment group at each post-treatment timepoint, mean change from diurnally adjusted baseline IOP at each timepoint, mean percent change from diurnally adjusted baseline IOP at each timepoint, mean diurnal IOP at other visits, and mean change from the baseline mean diurnal IOP at each visits.
|
7-28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
February 9, 2013
First Submitted That Met QC Criteria
February 11, 2013
First Posted (Estimate)
February 12, 2013
Study Record Updates
Last Update Posted (Estimate)
March 17, 2014
Last Update Submitted That Met QC Criteria
February 17, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PG286-CS202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
Santen Inc.Completed
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on PG286 Ophthalmic Solution 0.5%
-
Aldeyra Therapeutics, Inc.CompletedDry Eye SyndromesUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed
-
Rigel PharmaceuticalsCompletedChronic Graft-versus-host DiseaseUnited States
-
Rigel PharmaceuticalsCompletedKeratoconjunctivitis SiccaUnited States
-
pH PharmaCompletedNormal Tension GlaucomaKorea, Republic of
-
VivaVision Biotech, IncRecruitingInflammationUnited States
-
Seinda Pharmaceutical Guangzhou CorporationCompleted
-
Rigel PharmaceuticalsCompletedKeratoconjunctivitis SiccaUnited States